Vice President of Content, OncLive and Cancer Network
Gina Mauro is your lead editorial contact for OncLive. She joined the company in 2015 and has held various positions on OncLive; she is also the on-air correspondent for OncLive News Network: On Location. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com
January 4, 2021 — The pivotal phase 2/3 RINGSIDE trial, which is evaluating the potent, selective oral gamma secretase inhibitor AL102, has been permitted to proceed and can potentially be used as a registrational study for adolescent and adult patients with desmoid tumors.
December 29, 2020 - The FDA has granted an orphan drug designation to Annamycin for the treatment of patients with soft tissue sarcomas.
Treatment with iodine (131I) apamistamab (Iomab-B) conditioning led to a 100% bone marrow transplant rate and engraftment in patients with active relapsed/refractory acute myeloid leukemia who are older than 55 years old, according to results of a single ad hoc interim analysis of the phase 3 SIERRA study.
The filing of a new drug application has been initiated with the FDA for surufatinib for the treatment of patients with pancreatic and non-pancreatic neuroendocrine tumors.
Nicholas C. Rohs, MD, highlights the influx of clinical trials and the addition of immunotherapy in the adjuvant setting of lung cancer.
December 22, 2020 — Enobosarm demonstrated clinical benefit at varying dose levels in patients with androgen receptor–positive, estrogen receptor–positive metastatic breast cancer.
December 21, 2020 — The 5-drug regimen of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide showed a tolerable safety profile and encouraging antitumor activity with complete responses in patients with relapsed/refractory diffuse large B-cell lymphoma.
December 21, 2020 - The National Comprehensive Cancer Network has added 3 selinexor combination regimens to its Clinical Practice Guidelines in Oncology for previously treated patients with multiple myeloma.
R. Lor Randall, MD, FACS, discusses the concept and prospect of up-front resection in osteosarcoma from the Osteosarcoma Collaborative.
Balazs Halmos, MD discusses the year 2021 and how it will encompass a bigger focus on neoadjuvant and adjuvant trials, more novel molecular compounds for more select subgroups, and a migration of circulating tumor DNA into a more minimal residual disease–based setting.
December 14, 2020 - The combination of neratinib and capecitabine showed a 34% reduction in the risk of disease progression or death compared with lapatinib and capecitabine in patients with HER2-positive breast cancer who had central nervous system metastases at baseline.
Circulating tumor DNA positivity identified patients with high-risk muscle-invasive urothelial cancer who were likely to derive improvements in disease-free survival and overall survival from adjuvant atezolizumab vs observation.
December 11, 2020 - The combination of plinabulin and pegfilgrastim was 53% more effective in reducing the incidence of profound neutropenia compared with pegfilgrastim alone in patients undergoing chemotherapy, according to full findings of the phase 3 PROTECTIVE-2 trial.
December 11, 2020 - Oncolytic viral therapy has been heavily investigated across oncology, but plenty of work still lies ahead to determine how this treatment approach can be applied in gastrointestinal malignancies.
December 10, 2020 - The GP2 immunotherapy plus granulocyte-macrophage colony-stimulating factor demonstrated potent responses and a 100% disease-free survival in patients with HER2/neu 3–positive disease who received adjuvant trastuzumab.
December 10, 2020 - Amcenestrant elicited antitumor activity in heavily pretreated, postmenopausal women with advanced or metastatic estrogen receptor–positive breast cancer.
December 10, 2020 - Fam-trastuzumab deruxtecan-nxki continued to showcase impressive signals of efficacy, including prolonged, durable responses and overall survival rates, as well as a tolerable safety profile in patients with HER2-positive metastatic breast cancer.
December 9, 2020 - The combination of oral paclitaxel and encequidar led to an estimated 26.5% reduction in the risk of death compared with intravenous paclitaxel in patients with metastatic breast cancer, according to updated phase 3 findings of the KX-ORAX-001 trial.
December 9, 2020 - The combination of abemaciclib and standard endocrine therapy showed a 28.7% reduction in the risk of invasive disease recurrence or death compared with endocrine therapy alone in patients with high-risk, early hormone receptor–positive, HER2-negative breast cancer.
Asciminib demonstrated a statistically significant and clinically meaningful improvement in the major molecular response rate at 24 weeks compared with bosutinib in patients with chronic myeloid leukemia in chronic phase who have received at least 2 prior TKIs.
December 8, 2020 - Fixed-duration treatment with mosunetuzumab elicited high, durable, and consistent responses across numerous subgroups of patients with follicular lymphoma.
LOXO-305, an investigational, highly selective, non-covalent BTK inhibitor, demonstrated an investigator-assessed 63% objective response rate in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
Panobinostat, given at a 20-mg 3-times-weekly or twice-weekly dosing schedule, in combination with subcutaneous bortezomib and dexamethasone showed durable responses and an acceptable safety profile in patients with relapsed or relapsed/refractory myeloma.
What started out as a journey to better understand regulatory T cells has now led to an intriguing approach with an investigational cell therapy designed to prevent the risk of graft-versus-host disease and to improve relapse-free survival rates in patients undergoing hematopoietic stem cell transplantation.
December 6, 2020 - Odronextamab, is a novel CD20xCD3 bispecific antibody, continues to show intriguing antitumor activity and an acceptable safety profile in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, including those who have previously received chimeric antigen receptor T-cell therapy.
December 6, 2020 - UCART22, an allogeneic off-the-shelf CD22-directed T-cell product, showed no unexpected toxicities at 2 dose levels and had early signs of activity in adult patients with relapsed/refractory CD22-positive B-cell acute lymphoblastic leukemia.
December 5, 2020 - Axicabtagene ciloleucel demonstrated high rates of durable responses in patients with indolent non-Hodgkin lymphoma.
